0QIU:LSE Novo Nordisk A/S Class B

DKK 911.10 0.00 0
Icon

Novo Nordisk A/S Class B (0QIU:LSE) Stock Analysis and Price Targets

COMMON STOCK | | LSE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

DKK 911.10

0.00 (0.00)%

DKK 19.90B

7.84K

N/A

N/A
Icon

0QIU:LSE

Novo Nordisk A/S Class B (DKK)
COMMON STOCK | LSE
DKK 911.10
0.00 0
Take a Tour
Target Discuss Watchlist
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

DKK 19.90B

N/A

DKK 911.10

Novo Nordisk A/S Class B (0QIU:LSE) Stock Forecast

N/A

Based on the Novo Nordisk A/S Class B stock forecast from 0 analysts, the average analyst target price for Novo Nordisk A/S Class B is not available over the next 12 months. Novo Nordisk A/S Class B’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Novo Nordisk A/S Class B is Very Bullish, which is based on 1 positive signals and 0 negative signals. At the last closing, Novo Nordisk A/S Class B’s stock price was DKK 911.10. Novo Nordisk A/S Class B’s stock price has changed by +2.41% over the past week, +6.05% over the past month and +58.23% over the last year.

No recent analyst target price found for Novo Nordisk A/S Class B
No recent average analyst rating found for Novo Nordisk A/S Class B

Company Overview Novo Nordisk A/S Class B

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the ...Read More

https://www.novonordisk.com

Novo Allé 1, Bagsvaerd, Denmark, 2880

59,337

December

DKK

UK

Adjusted Closing Price for Novo Nordisk A/S Class B (0QIU:LSE)

Unadjusted Closing Price for Novo Nordisk A/S Class B (0QIU:LSE)

Share Trading Volume for Novo Nordisk A/S Class B Shares

Compare Performance of Novo Nordisk A/S Class B Shares

Symbol Capital Gain Dividend Return Total Return

Technical Indicators for 0QIU:LSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Novo Nordisk A/S Class B (Sector: )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
0R37:LSE
Berkshire Hathaway Inc 0.00 (0.00%) DKK9,223,372,036.85B N/A N/A

ETFs Containing 0QIU

Symbol Name 0QIU's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Novo Nordisk A/S Class B (0QIU:LSE) Stock

Stock Target Advisor's fundamental analysis for Novo Nordisk A/S Class B's stock is Very Bullish.

Unfortunately we do not have enough data on 0QIU:LSE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 0QIU:LSE's stock to indicate what its average analyst target is.

0QIU:LSE stock's Price/Earning ratio is 0.39. Based on this 0QIU:LSE may be undervalued for its sector.

The last closing price of 0QIU:LSE's stock was DKK 911.10.

The most recent market capitalization for 0QIU:LSE is DKK 19.90B.

Unfortunately we do not have enough analyst data on 0QIU:LSE's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Novo Nordisk A/S Class B's stock.

As per our most recent records Novo Nordisk A/S Class B has 59,337 Employees.

Novo Nordisk A/S Class B's registered address is Novo Allé 1, Bagsvaerd, Denmark, 2880. You can get more information about it from Novo Nordisk A/S Class B's website at https://www.novonordisk.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Stock Target Advisor

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like